According to the United States (U.S.) Department of Health & Human Services, back pain accounts for approximately 13.4 million physician office visits and 3.7 million emergency room visits annually. Degeneration of an intervertebral disc that results in functionally limiting low back pain is a common condition that prompts patients to seek treatment. To eliminate or reduce pain and restore quality of life, patients with acute, debilitating pain may require spinal fusion.
During the forecast period covered by this report, the combined U.S. market for osteobiologic and bone growth stimulation products for spine surgery is projected to increase at a compound annual rate of 2.8%, reaching an estimated $2,110.5 million in the year 2016.
This dynamic new report from Medtech Insight includes analyses of the U.S. markets for allograft bone products, electrical osteogenic stimulators, recombinant human bone morphogenetic proteins, and synthetic bone grafts used in spine surgery. Also included in this report are company profiles of the leading competitors in these markets, as well as a clinical overview of the most common spinal diseases/disorders for which spinal fusion is indicated.
Reports are produced exclusively by Medtech Insight, through extensive primary and secondary research among the clinicians, researchers, and competitors in the marketplace, and draw upon the industry expertise of a network of industry insiders. Medtech Insight exhaustively corroborates the data as a baseline for completing forward-looking analysis and providing insight into product, technology and market evolution.